Evolocumab - a new medicine for hypercholesterinemia treatment


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Increased level of low-density lipoproteins cholesterine (CH LDL) in blood plasma in parallel with arterial hypertension and smoking is a main modified risk factor of cardiovascular diseases development. Its correction lays in the basis of clinical recommendations concerning cardiovascular diseases prevention and treatment, although in real clinical practice only minor part of patients of high and very high cardiovascular risk arrives aimed CH LDL indexes. Nowadays it became possible to use a new lipid lowering drug for hypercholesterinemia correction. That is protease inhibitor evolocumab. It was shown during clinical examinations before, that in patients with primary hyperlipidemia and mixed dyslipidemia addition of evolocumab to lipid lowering therapy by statine or ezetemibe lets additionally decrease the level of CH-LPL at 50-70%, and, what is more important, the risk of arising the cardiovascular events such as myocardial infarction and brain stroke is also significantly decreasing in parallel with CH-LPL decrease. The aim of current review is to show practical physicians the information concerning efficacy and safety of PCSK9 inhibitor evolocumab use in different groups of patients.

Full Text

Restricted Access

About the authors

Alexey N. Meshkov

FSBI «National Medical Research Centre of Preventive Medicine» of the Ministry of Health of Russia

Email: meshkov@lipidclinic.ru
Head of the Laboratory of Molecular Genetics

References

  1. Piepoli M.F., Hoes A.W., Agewall S., Albus C., Brotons C., Catapano A.L., Cooney M.T., Corrà U., Cosyns B., Deaton C., Graham I., Hall M.S., Hobbs F.D., Lochen M.L., Löllgen H., Marques-Vidal P., Perk J., Prescott E., Redon J., Richter D.J., Sattar N., Smulders Y., Tiberi M., Bart van der Worp H., van Dis I., Verschuren W.M. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Atherosclerosis. 2016;252:207-74.
  2. Ference B.A., Ginsberg H.N., Graham I., Ray K.K., Packard C.J., Bruckert E., Hegele R.A., Krauss R.M., Raal F.J., Schunkert H., Watts G.F., Borén J., Fazio S., Horton J.D., Masana L., Nicholls S.J., Nordestgaard B.G., van de Sluis B., Taskinen M.R., Tokgözoglu L., Landmesser U., Laufs U., Wiklund O., Stock J.K., Chapman M.J., Catapano A.L. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur. Heart. J. 2017;38(32):2459-72.
  3. Chiang C.E., Ferrières J., Gotcheva N.N., Raal F.J., Shehab A., Sung J., Henriksson K.M., Hermans M.P. Suboptimal Control of Lipid Levels: Results from 29 Countries Participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS). J. Atheroscler. Thromb. 2015;22:567-87.
  4. Бойцов С.А., Хомицкая Ю.В. Централизованное исследование по оценке эффективности лечения гиперхолестеринемии в России (CEPHEUS). Кардиоваскулярная терапия и профилактика. 2013;12 (4):67-74. [Boytsov SA, Khomitskaya YuV. Centralised Survey on the Undertreatment of the Hypercholesterolemia in Russia (CEPHEUS). Kardiovaskulyarnaya Terapiya i Profilaktika. 2013;12 (4):67-74 (In Russian)].
  5. Оганов Р.Г., Кухарчук В.В., Арутюнов Г.П., Галявич А.С., Гуревич В.С., Дупляков Д.В., Карпов Ю.А., Кобалава Ж.Д., Константинов В.О., Марцевич С.Ю., Панов А.В., Сергиенко И.В., Скибицкий В.В., Смоленская О.Г., Сусеков А.В., Тюрин В.П., Шалаев С.В., Манешина О.А., Бригида О.В. Сохраняющиеся нарушения показателей липидного спектра у пациентов с дислипидемией, получающих статины, в реальной клинической практике в российской федерации (российская часть исследования DYSIS). Кардиоваскулярная терапия и профилактика. 2012;12(4):70-8. [Oganov RG, Kukharchuk V.V., Arutyunov G. P, Galyavich A.S., Gurevich V.S., Duplyakov D.V., Karpov Yu. A., Kobalava Zh. D., Konstantinov V.O., Martsevich S. Yu., Panov A.V., Sergienko I.V., Skibitskyi V.V., Smolenskaya O.G., Susekov A.V., Tyurin V. P, Shalaev S.V., Maneshina O.A., Brigida O.V. Persistent dyslipidemia in statin-treated patients: Russian real-world clinical practice data (Russian part of the DYSIS Study). Kardiovaskulyarnaya Terapiya i Profilaktika. 2012;12(4):70-8 (In Russian)].
  6. Сметнев С.А., Ершова А.И., Богданова Р.С., Мешков А.Н., Бойцов С.А. Эффективность гиполипидемической терапии на амбулаторном и госпитальном этапах у пациентов высокого и очень высокого сердечно-сосудистого риска за период 2011-2015 годы. Рациональная фармакотерапия в кардиологии. 2016;12(6):622-30. [Smetnev S.A., Ershova A.I., Bogdanova R.S., Meshkov A.N., Boytsov S.A. The Effectiveness of Outpatient and Hospital Lipid-lowering Therapy in Patients with High and Very High Cardiovascular Risk during 2011-2015. Rational Pharmacotherapy in Cardiology. 2016;12(6):622-630 (In Russian)].
  7. Ершова А.И., Мешков А.Н., Якушин С.С., Лукьянов М.М., Мосейчук К.А., Марцевич С.Ю., Загребельный А.В., Воробьев А.Н., Переверзева К.Г., Правкина Е.А., Козминский А.Н., Бойцов С.А. Диагностика и лечение больных с выраженной гиперхолестеринемией в реальной амбулаторно-поликлинической практике (по данным регистра РЕКВАЗА). Рациональная фармакотерапия в кардиологии. 2014;10(6):612-6. [Ershova A.I., Meshkov A.N., Yakushin S.S., Loukianov M.M., Moseychuk K.A., Martsevich S.Yu., Zagrebelnyy A.V., Vorobyev A.N., Pereverzeva K.G., Pravkina E.A., Kozminskiy A.N., Boytsov S.A. Diagnosis and treatment of patients with severe hypercholesterolemia in real outpatient practice (according to the RECVASA registry). Rational Pharmacotherapy in Cardiology. 2014;10(6):612-616. (In Russian)].
  8. Catapano A.L., Graham I., De Backer G., Wiklund O., Chapman M.J., Drexel H., Hoes A.W., Jennings C.S., Landmesser U., Pedersen T.R., Reiner Z., Riccardi G., Taskinen M.R., Tokgozoglu L., Verschuren W.M., Vlachopoulos C., Wood D.A., Zamorano J.L. 2016 ESC/ EAS Guidelines for the Management of Dyslipidaemias. Eur. Heart J. 2016;37(39):2999-3058.
  9. Мешков А.Н., Малышев П.П., Кухарчук В.В. Семейная гиперхолестеринемия в России: генетическая и фенотипическая характеристика. Терапевтический архив. 2009;81(9):23-8. [Meshkov A.N., Malyshev P.P., Kukharchuk V.V. Familial hypercholesterolemia in Russia: genetic and phenotypic characteristics. Ter. Arkh. 2009;81(9):23-8 (In Russian)].
  10. De Backer G., Besseling J., Chapman J., Hovingh G.K., Kastelein J.J., Kotseva K., Ray K., Reiner Z., Wood D., De Bacquer D.; EUROASPIRE Investigators. Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology. Atherosclerosis. 2015 Jul;241(1):169-75.
  11. Susekov A., Meshkov A., Korneva V., Ershova A., Konstantinov V., Kuznetsova T., Rozkova Т. Clinical characteristics and LDL-C achievement rates in 506 FH patients from 4 Russian lipid clinics. J. Clin. Lipidol. 2016;10(3):698.
  12. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C., Blackwell L., Emberson J., Holland L.E., Reith C., Bhala N., Peto R., Barnes E.H., Keech A., Simes J., Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-81.
  13. Мешков А.Н. Гиполипидемическая эффективность розувастатина в сравнении с другими статинами. Рациональная фармакотерапия в кардиологии. 2012;8(5):691-3. [Meshkov AN. Lipid-lowering efficacy of rosuvastatin compared with other statins. Rational Pharmacotherapy in Cardiology. 2012;8(5):691-693. (In Russian)].
  14. Raal F.J., Stein E.A., Dufour R., Turner T., Civeira F., Burgess L., Langslet G., Scott R., Olsson A.G., Sullivan D., Hovingh G.K., Cariou B., Gouni-Berthold I., Somaratne R., Bridges I., Scott R., Wasserman S.M., Gaudet D.; RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebocontrolled trial. Lancet. 2015;385:331-40.
  15. Nissen S.E., Stroes E., Dent-Acosta R.E., Rosenson R.S., Lehman S.J., Sattar N., Preiss D., Bruckert E., Ceska R., Lepor N., Ballantyne C.M., Gouni-Berthold I., Elliott M., Brennan D.M., Wasserman S.M., Somaratne R., Scott R., Stein E.A.; GAUSS-3 Investigators. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. JAMA. 2016;315(15):1580-90.
  16. Robinson J.G., Nedergaard B.S., Rogers W.J., Fialkow J., Neutel J.M., Ramstad D., Somaratne R., Legg J.C., Nelson P., Scott R., Wasserman S.M., Weiss R.; LAPLACE-2 Investigators. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014;311(18):1870-82.
  17. Sabatine M.S., Giugliano R.P., Keech A.C., Honarpour N., Wiviott S.D., Murphy S.A., Kuder J.F., Wang H., Liu T., Wasserman S.M., Sever P.S., Pedersen T.R.; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N. Engl. J. Med. 2017;376(18):1713-22.
  18. Zaid A., Roubtsova A., Essalmani R., Marcinkiewicz J., Chamberland A., Hamelin J., Tremblay M., Jacques H., Jin W., Davignon J., Seidah N.G., Prat A. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology. 2008;48:646-54.
  19. Goldstein J.L., Brown MS. The LDL receptor. Arterioscler. Thromb. Vasc. Biol. 2009;29(4):431-8.
  20. Мешков А.Н., Калинина М.В., Ершова А.И., Косенков Е.И., Щербакова Н.В., Рожкова Т.А., Масенко В.П., Кухарчук В.В., Бойцов С.А. Уровень PCSK9 в семьях больных семейной гиперхолестеринемией. Атеросклероз и дислипидемии. 2012;1(6);12-5. [Meshkov A.N., Kalinin M.V., Ershov A.I., Kosenkov E., Shcherbakova N.V., Rozhkov T.A., Masenko V.P., Kuharchuk V.V., Boitsov S.A. The level of PCSK9 in patients with familial hypercholesterolemia. Atherosclerosis and Dyslipidaemias. 2012;1(6):12-5. (In Russian)].
  21. Careskey H.E., Davis R.A., Alborn W.E., Troutt J.S., Cao G., Konrad R.J. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J. Lipid Res. 2008;49(2):394-8.
  22. Lakoski S.G., Lagace T.A., Cohen J.C., Horton J.D., Hobbs H.H. Genetic and metabolic determinants of plasma PCSK9 levels. J. Clin. Endocrinol. Metab. 2009;94(7):2537-43.
  23. Dias C.S., Shaywitz A.J., Wasserman S.M., Smith B.P., Gao B., Stolman D.S., Crispino C.P., Smirnakis K.V., Emery M.G., Colbert A., Gibbs J.P., Retter M.W., Cooke B.P., Uy S.T., Matson M., Stein E.A. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J. Am. Coll. Cardiol. 2012;60(19):1888-98.
  24. Nicholls S.J., Puri R., Anderson T., Ballantyne C.M., Cho L., Kastelein J.J., Koenig W., Somaratne R., Kassahun H., Yang J., Wasserman S.M., Scott R., Ungi I., Podolec J., Ophuis A.O., Cornel J.H., Borgman M., Brennan D.M., Nissen S.E. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016;316(22):2373-84.
  25. Коновалов Г.А., Бажан С.С. Эволокумаб: инновационные возможности снижения холестерина липопротеидов низкой плотности, липопротеида (а) и управления сердечно-сосудистым риском. Кардиология: новости, мнения, обучение. 2017 №2(13):45-56. [Konovalov G.A., Bazhan S.S. Evolocumab: innovative opportunities for LDL-C, LP (a) lowering and cardiovascular risk management. Cardiology: news, opinions, training. 2017;2(13):45-56. (In Russian)].
  26. Сусеков А.В., Яфарова А.А., Щербакова М.Ю., Мешков А.Н. Регрессия ксантоматоза у 12-летнего пациента с гомозиготной формой семейной гиперхолестеринемии: клинический случай. Педиатрия. Приложение к журналу Consilium Medicum. 2016;3:103-8. Susekov A.V., Yafarova A.A., Shcherbakova M.Yu., Meshkov A.N. Regression of xanthomatosis in a 12-year-old patient with homozygous familial form of hypercholesterolemia: a clinical case. Pediatric supplement Consilium Medicum. 2016;3:103-8 (In Russian)].

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies